Celularity financials
$1.37−2.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $26.6M | $54.2M | $22.8M | $18.0M | $21.3M |
| Gross profit | $6.5M | $39.2M | $6.8M | -$1.7M | $11.7M |
| Gross margin | 24.4% | 72.4% | 29.7% | −9.4% | 54.8% |
| Operating income | -$61.3M | -$38.4M | -$192.3M | -$25.6M | -$109.1M |
| Net income | -$91.8M | -$57.9M | -$196.3M | $14.2M | -$100.1M |
| Net margin | −345.8% | −106.8% | −862.0% | 79.0% | −469.3% |
| Diluted EPS | $-3.59 | $-2.64 | $-11.02 | $0.95 | $-14.90 |
| EBITDA | -$54.0M | -$30.6M | -$67.2M | -$138.8M | -$141.4M |
| Operating cash flow | -$13.3M | -$6.4M | $62.7M | -$137.9M | -$110.1M |
| Free cash flow | -$13.3M | -$8.1M | $61.6M | -$143.1M | -$116.3M |
| Diluted shares | 25.6M | 21.9M | 17.8M | 15.0M | 6.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $6.2M | $738.0K | $227.0K | $14.0M | $37.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $47.8M | $6.4M | $39.2M | $37.6M | $31.1M |
| Total assets | $107.3M | $132.7M | $143.9M | $401.1M | $414.1M |
| Total liabilities | $145.4M | $123.8M | $102.9M | $202.2M | $314.7M |
| Shareholders' equity | -$38.1M | $8.8M | $41.0M | $198.9M | $99.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology